blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3129485

EP3129485 - CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS [Right-click to bookmark this link]
StatusPatent maintained as amended
Status updated on  18.11.2022
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  10.05.2019
FormerGrant of patent is intended
Status updated on  11.10.2018
FormerExamination is in progress
Status updated on  25.09.2018
FormerGrant of patent is intended
Status updated on  13.05.2018
FormerExamination is in progress
Status updated on  20.10.2017
FormerRequest for examination was made
Status updated on  13.01.2017
FormerThe international publication has been made
Status updated on  31.10.2016
Most recent event   Tooltip18.11.2022Patent maintained (B2 publication)published on 21.12.2022  [2022/51]
Applicant(s)For all designated states
Editas Medicine, Inc.
300 Third Street
First Floor
Cambridge, MA 02142 / US
[2017/07]
Inventor(s)01 / REYON, Deepak
170 Maple Street
Apt. 110
Malden, MA 02148 / US
02 / MAEDER, Morgan, L.
41 Spring Park Avenue
Unit 1
Jamaica Plain, MA 02130 / US
03 / FRIEDLAND, Ari, E.
661 Tremont Street 5
Boston, MA 02118 / US
04 / WELSTEAD, G., Grant
20 Andrew Street
Cambridge, MA 02139 / US
05 / BUMCROT, David, A.
30 Leicester Road
Belmont, MA 02478 / US
 [2017/07]
Representative(s)Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
[2019/24]
Former [2017/07]Atkinson, Jennifer
Barker Brettell LLP
100 Hagley Road
Edgbaston
Birmingham B16 8QQ / GB
Application number, filing date15721376.001.04.2015
[2017/07]
WO2015US23960
Priority number, dateUS201461977488P09.04.2014         Original published format: US 201461977488 P
[2017/07]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2015157070
Date:15.10.2015
Language:EN
[2015/41]
Type: A2 Application without search report 
No.:EP3129485
Date:15.02.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 15.10.2015 takes the place of the publication of the European patent application.
[2017/07]
Type: B1 Patent specification 
No.:EP3129485
Date:12.06.2019
Language:EN
[2019/24]
Type: B2 New European patent specification 
No.:EP3129485
Date:21.12.2022
Language:EN
[2022/51]
Search report(s)International search report - published on:EP30.12.2015
ClassificationIPC:C12N15/113, A61K31/7088
[2017/07]
CPC:
C12N15/1138 (EP,US); C12N9/22 (EP,US); C12N2310/10 (EP,US);
C12N2310/20 (EP,US); C12N2320/34 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/07]
TitleGerman:CRISPR/CAS-ASSOZIIERTE VERFAHREN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON MUKOVISZIDOSE[2017/07]
English:CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS[2017/07]
French:MÉTHODES ET COMPOSITIONS SE RAPPORTANT À CRISPR/CAS ET DESTINÉES AU TRAITEMENT DE LA FIBROSE KYSTIQUE[2017/07]
Entry into regional phase31.10.2016National basic fee paid 
31.10.2016Designation fee(s) paid 
31.10.2016Examination fee paid 
Examination procedure31.10.2016Examination requested  [2017/07]
31.10.2016Date on which the examining division has become responsible
25.05.2017Amendment by applicant (claims and/or description)
18.10.2017Despatch of a communication from the examining division (Time limit: M04)
27.12.2017Reply to a communication from the examining division
19.01.2018Despatch of a communication from the examining division (Time limit: M02)
14.03.2018Reply to a communication from the examining division
14.05.2018Communication of intention to grant the patent
21.09.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
12.10.2018Communication of intention to grant the patent
18.02.2019Fee for grant paid
18.02.2019Fee for publishing/printing paid
18.02.2019Receipt of the translation of the claim(s)
Divisional application(s)EP19157864.0  / EP3556858
Opposition(s)Opponent(s)01  28.01.2020  11.03.2020  ADMISSIBLE
James Poole Limited
One Southampton Row
London WC1B 5HA / GB
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 [2021/37]
Former [2020/10]
Opponent(s)01  28.01.2020    ADMISSIBLE
James Poole Limited
One Southampton Row
London WC1B 5HA / GB
Opponent's representative
Marshall, Cameron John
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
26.03.2020Invitation to proprietor to file observations on the notice of opposition
08.02.2022Legal effect of interlocutory decision in opposition
08.02.2022Date of oral proceedings
18.03.2022Despatch of minutes of oral proceedings
22.03.2022Despatch of interlocutory decision in opposition
22.07.2022Despatch of communication that the patent will be maintained as amended
27.10.2022Fee for printing new specification paid
Fees paidRenewal fee
27.04.2017Renewal fee patent year 03
27.04.2018Renewal fee patent year 04
29.04.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU01.04.2015
AL12.06.2019
AT12.06.2019
CY12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
MK12.06.2019
MT12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
LU01.04.2020
[2022/32]
Former [2022/28]HU01.04.2015
AL12.06.2019
AT12.06.2019
CY12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
MT12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
LU01.04.2020
Former [2021/08]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
LU01.04.2020
Former [2020/52]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
MC12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/36]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/24]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
PL12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SI12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
IS24.02.2020
Former [2020/22]AL12.06.2019
AT12.06.2019
CZ12.06.2019
DK12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/17]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
SM12.06.2019
TR12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/13]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
SM12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/12]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
IT12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
IS12.10.2019
PT14.10.2019
Former [2020/11]AL12.06.2019
AT12.06.2019
CZ12.06.2019
EE12.06.2019
ES12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
SK12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
Former [2020/10]AL12.06.2019
AT12.06.2019
CZ12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RO12.06.2019
RS12.06.2019
SE12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
PT14.10.2019
Former [2020/09]AL12.06.2019
CZ12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
SE12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
Former [2019/51]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
SE12.06.2019
BG12.09.2019
NO12.09.2019
GR13.09.2019
Former [2019/50]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
LV12.06.2019
RS12.06.2019
SE12.06.2019
NO12.09.2019
GR13.09.2019
Former [2019/49]AL12.06.2019
FI12.06.2019
HR12.06.2019
LT12.06.2019
SE12.06.2019
NO12.09.2019
Former [2019/48]FI12.06.2019
LT12.06.2019
SE12.06.2019
NO12.09.2019
Former [2019/47]FI12.06.2019
LT12.06.2019
NO12.09.2019
Cited inInternational search[XI]   GERALD SCHWANK ET AL: "Functional Repair of CFTR by CRISPR/Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients", CELL STEM CELL, vol. 13, no. 6, 1 December 2013 (2013-12-01), pages 653 - 658, XP055102691, ISSN: 1934-5909, DOI: 10.1016/j.stem.2013.11.002 [X] 1,2,4,5,8,10,12,19,26,31-33,35,36,39,40,47,54,59,132,138,141-144,146,149,152,155-160 * the whole document * [I] 1,2,4,5,8,10-33,35,36,39-77,79,82-194

DOI:   http://dx.doi.org/10.1016/j.stem.2013.11.002
 [X]   JENNIFER HOLLYWOOD: "Cystic fibrosis gene repair: correction of [Delta]F508 using ZFN and CRISPR/Cas9 guide RNA gene editing tools", 1 January 2013 (2013-01-01), pages 1 - 193, XP055209264, Retrieved from the Internet [retrieved on 20150824] [X] 1,2,4,5,19,26,31-33,35,36,47,54,59-61,63,132,138,141-144,146,149,152,155-160 * page 132 - page 151 *
 [A]   PAULINE T. IKPA ET AL: "Cystic fibrosis: Toward personalized therapies", THE INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, vol. 52, 20 February 2014 (2014-02-20), pages 192 - 200, XP055209406, ISSN: 1357-2725, DOI: 10.1016/j.biocel.2014.02.008 [A] 1,2,4,5,8,10-33,35,36,39-77,79,82-194 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.biocel.2014.02.008
OppositionUS2014242700
 US2014242700
   HOLLYWOOD J. A. ET AL.: "Strategy to correct >80% of CF-causing mutations using CRISPR/Cas9 and mini- gene constructs", NEW FRONTIERS IN BASIC SCIENCE OF CYSTIC FIBROSIS, 26 March 2014 (2014-03-26) - 29 March 2014 (2014-03-29), XP055707164
   TSUI ET AL.: "The Cystic Fibrosis Gene: A Molecular Genetic Perspective", COLD SPRING HARB PERSPECT IN MED., vol. 3, no. 2, 1 February 2013 (2013-02-01), pages a009472, XP055087619

DOI:   http://dx.doi.org/10.1101/cshperspect.a009472
   HSU ET AL.: "Development and Applications of CRISPR-Cas9 for Genome Engineering", CELL, vol. 157, no. 6, 1 June 2014 (2014-06-01), pages 1262 - 1278, XP055694974

DOI:   http://dx.doi.org/10.1016/j.cell.2014.05.010
   LI ET AL.: "In vivo genome editing restores haemostasis in a mouse model of haemophilia", NATURE, vol. 475, no. 7355, 26 June 2011 (2011-06-26), pages 217 - 221, XP002688791

DOI:   http://dx.doi.org/10.1038/nature10177
   LOMBARDO ET AL.: "Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector", NATURE BIOTECHNOLOGY, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1298 - 1306, XP002465562

DOI:   http://dx.doi.org/10.1038/nbt1353
   LEE ET AL.: "Correction of the F508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair", BIORESEARCH OPEN ACCESS, vol. 1, no. 3, 1 June 2012 (2012-06-01), pages 99 - 108, XP055143593

DOI:   http://dx.doi.org/10.1089/biores.2012.0218
   HOLLYWOOD J. A. ET AL.: "Strategy to correct >80% of CF-causing mutations using CRISPR/Cas9 and mini- gene constructs", NEW FRONTIERS IN BASIC SCIENCE OF CYSTIC FIBROSIS, 26 March 2014 (2014-03-26) - 29 March 2014 (2014-03-29)
   TSUI ET AL.: "The Cystic Fibrosis Gene: A Molecular Genetic Perspective", COLD SPRING HARB PERSPECT IN MED., vol. 3, no. 2, 1 February 2013 (2013-02-01), pages a009472
   HSU ET AL.: "Development and Applications of CRISPR-Cas9 for Genome Engineering", CELL, vol. 157, no. 6, 1 June 2014 (2014-06-01), pages 1262 - 1278
   LI ET AL.: "In vivo genome editing restores haemostasis in a mouse model of haemophilia", NATURE, vol. 475, no. 7355, 26 June 2011 (2011-06-26), pages 217 - 221
   LOMBARDO ET AL.: "Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector", NATURE BIOTECHNOLOGY, vol. 25, no. 11, 1 November 2007 (2007-11-01), pages 1298 - 1306
   LEE ET AL.: "Correction of the F508 Mutation in the Cystic Fibrosis Transmembrane Conductance Regulator Gene by Zinc-Finger Nuclease Homology-Directed Repair", BIORESEARCH OPEN ACCESS, vol. 1, no. 3, 1 June 2012 (2012-06-01), pages 99 - 108
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.